アログリプチンが膵臓β細胞機能に及ぼす影響

基本情報

NCT ID

NCT01303055

ステータス

不明

試験のフェーズ

該当なし

試験タイプ

介入

目標被験者数

80

治験依頼者名

Aichi Gakuin University

概要

It is reported that pancreatic beta cell function is already declined at pre-diabetic stage, impaired glucose tolerance (IGT). It has not been clarified whether inhibitors of the dipeptidyl peptidase IV enzyme (DPP-IV inhibitors) improve beta cell function on human pancreas, however, if efficacy is ensured, they may become the first medicine to be chosen for treatments of type 2 diabetes and IGT. In this trial, a DPP-IV inhibitor, Alogliptin, or Metformin are given to diabetic patients whose HbA1c level is below 7.9%. Oral glucose tolerance test (OGTT) will be conducted before, a year after, and two years after the beginning of the trial and beta cell function will be evaluated.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)